放化疗同步治疗应用于中晚期宫颈癌患者的临床疗效  

Clinical efficacy of concurrent radiotherapy and chemotherapy in the treatment of advanced cervical cancer

作　　者：石常庆 Shi Changqing(Department of Oncology,Peixian People's Hospital,Peixian 221600,China)

机构地区：[1]沛县人民医院肿瘤内科,江苏沛县221600

出　　处：《实用妇科内分泌电子杂志》2024年第22期53-55,71,共4页Electronic Journal of Practical Gynecological Endocrinology

摘　　要：目的探讨放化疗同步治疗应用于中晚期宫颈癌患者的临床疗效。方法选取40例中晚期宫颈癌患者,按照电脑随机抽签法分为两组,各20例。对照组采用单一放疗治疗,研究组采用放化疗同步治疗,对比两组治疗效果。结果研究组鳞状细胞癌抗原(SCC)、癌胚抗原(CEA)及糖类抗原125(CA125)水平均较对照组明显降低(P<0.05)。研究组治疗总有效率为100%,高于对照组的75.00%(P<0.05)。结论中晚期宫颈癌患者采用放化疗同步治疗,可有效降低血清肿瘤标志物,治疗效果更显著,值得临床推广。Objective To explore the clinical efficacy of concurrent radiotherapy and chemotherapy in patients with advanced cervical cancer.Methods 40 patients with advanced cervical cancer were selected and were divide into two groups according to the computer random drawing method,with 20 cases in each group.The control group received single radiotherapy treatment,while the study group received concurrent radiotherapy and chemotherapy treatment.The treatment effects of the two groups were compared.Results The levels of squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA),and carbohydrate antigen 125(CA125)in the study group were significantly reduced compared to the control group(P<0.05).The total effective rate of the treatment in the study group was 100%,higher than 75.00%in the control group(P<0.05).Conclusion The concurrent radiotherapy and chemotherapy for patients with advanced cervical cancer can effectively reduce serum tumor markers,and the treatment effect is more significant,which is worthy of clinical promotion.

关 键 词：放化疗同步治疗 中晚期宫颈癌 临床疗效 

分 类 号：R73[医药卫生—肿瘤]